ERBB2 and carcinoma: Indeed, there are ongoing phase 1–2 trials investigating treatments combining anti-HER2 agents with some forms of TAM-directed therapy in HER2+ carcinomas, e.g., HER2-targeted immune-stimulating antibody conjugate locally activating the innate immune system [40] and anti-HER2 CAR macrophage therapy [41].